Intervacc receives positive CVMP opinion for Strangvac, a vaccine against equine strangles, in the EU
Stockholm, June 17, 2021 - Intervacc AB (“Intervacc”) announced today that the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of Strangvac within the EU. Strangvac is a vaccine against equine strangles, a highly contagious infectious disease that affects horses globally. Endorsement of the positive opinion by the European Commission is expected in the third quarter of 2021. “We are very excited to receive a positive opinion from the CVMP. It is a long-awaited vaccine and an important